COLTHERES

Modelling and predicting sensitivity to targeted therapies in colorectal cancers

Coordinatore	UNIVERSITA DEGLI STUDI DI TORINO    more  Organization address address: Via Giuseppe Verdi 8 city: TORINO postcode: 10124 contact info Titolo: Prof. Nome: Alberto Cognome: Bardelli Email: send email Telefono: +39 0119933235 Fax: +39 0119933225
Nazionalità Coordinatore	Italy [IT]
Sito del progetto	http://www.coltheres.eu/
Totale costo	8˙200˙254 €
EC contributo	5˙999˙300 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2010-two-stage
Funding Scheme	CP-FP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-01-01   -   2014-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITA DEGLI STUDI DI TORINO  Organization address address: Via Giuseppe Verdi 8 city: TORINO postcode: 10124 contact info Titolo: Prof. Nome: Alberto Cognome: Bardelli Email: send email Telefono: +39 0119933235 Fax: +39 0119933225	IT (TORINO)	coordinator	1˙507˙200.00
2	Horizon Discovery Limited  Organization address address: CAMBRIDGE RESEARCH PARK city: Cambridge postcode: CB25 9TL contact info Titolo: Dr. Nome: Christopher Cognome: Torrance Email: send email Telefono: 441224000000 Fax: 441224000000	UK (Cambridge)	participant	920˙520.00
3	STICHTING HET NEDERLANDS KANKER INSTITUUT  Organization address address: PLESMANLAAN 121 city: AMSTERDAM postcode: 1066 CX contact info Titolo: Prof. Nome: Rene Cognome: Bernards Email: send email Telefono: 31205121952 Fax: 31205121954	NL (AMSTERDAM)	participant	641˙200.00
4	KATHOLIEKE UNIVERSITEIT LEUVEN  Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Ms. Nome: Sofie Cognome: Heroes Email: send email Telefono: 3216329979 Fax: 3216326515	BE (LEUVEN)	participant	498˙400.00
5	Agendia BV  Organization address address: Science Park 406 city: Amsterdam postcode: 1098XH contact info Titolo: Dr. Nome: Iris Cognome: Simon Email: send email Telefono: +31 20 462 1542 Fax: +31 20 462 1505	NL (Amsterdam)	participant	490˙500.00
6	FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE  Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203 city: L'HOSPITALET DE LLOBREGAT postcode: 8908 contact info Titolo: Ms. Nome: Carole Cognome: Amroune Email: send email Telefono: +34 93 260 7245 Fax: +34 93 260 7219	ES (L'HOSPITALET DE LLOBREGAT)	participant	419˙200.00
7	THE UNIVERSITY OF LIVERPOOL  Organization address address: Brownlow Hill, Foundation Building 765 city: LIVERPOOL postcode: L69 7ZX contact info Titolo: Ms. Nome: Jenny Cognome: Lawson Email: send email Telefono: 441518000000 Fax: 441518000000	UK (LIVERPOOL)	participant	348˙700.00
8	FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON  Organization address city: Barcelona postcode: 8035 contact info Titolo: Dr. Nome: Alejandro Cognome: Piris Giménez Email: send email Telefono: 34934893021 Fax: 34934893884	ES (Barcelona)	participant	333˙900.00
9	SWISS INSTITUTE OF BIOINFORMATICS  Organization address address: Rue Michel Servet 1 city: GENEVE postcode: 1211 contact info Titolo: Ms. Nome: Jocelyne Cognome: Bocquet Email: send email Telefono: +41 21 692 4058 Fax: +41 21 692 4055	CH (GENEVE)	participant	320˙880.00
10	AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA  Organization address address: PIAZZA OSPEDALE MAGGIORE 3 city: MILANO postcode: 20162 contact info Titolo: Dr. Nome: Salvatore Cognome: Siena Email: send email Telefono: +39 02 6444 2291 Fax: +39 02 6444 2957	IT (MILANO)	participant	314˙800.00
11	ARTTIC IN BRUSSELS SPRL  Organization address address: RUE DE LIVOURNE 7 bte 4 city: BRUXELLES postcode: 1060 contact info Titolo: Mr. Nome: Paul Cognome: Crompton Email: send email Telefono: 3226723339 Fax: 3226721646	BE (BRUXELLES)	participant	204˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk and patient-response stratification criteria, which can then be used to rationally develop companion diagnostic assays and more stream-lined clinical trials. COLTHERES will address these key issues by: 1) Molecularly profiling colon cancer patient samples using multiple ‘omics based technologies for co-segregating lesions that could impart resistance to existing and emerging targeted therapies 2) The building and screening of predictive in vitro models based on this data, to enable the rapid and empirical determination of drug resistance biomarkers 3) The use of these models and of the clinical studies to prospectively screen for genes mediating resistance and sensitivity to targeted therapies in CRCs 4) The building of new algorithms to significantly accelerate the design of rational therapies, by integrating more predictive models, assays and biomarkers into all phases of drug discovery; including novel phase-0 (xenopatients) studies 5) The design of innovative and focused biomarker driven phase II trials based on knowledge gathered within the project

COLTHERES has assembled a unique consortium, from both academia and industrial SMEs, of world- experts in the areas of; • clinical design of innovative biomarker trials and improved therapeutic strategies • ‘omics technologies including genomic, transcriptomic, epigenomic and proteomic profiling • Functional genomic and disease model-generation • Bio-informatics and data analysis, to handle and interrogate the complexity of the data generated through the various approaches'

Introduzione (Teaser)

A main limitation of targeted therapies in colorectal cancer is the emergence of secondary resistance. European scientists are prospectively screening for genes that mediate such acquired resistance, aiming to identify specific drug resistance biomarkers.